"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 4 | 4 | 8 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 5 | 7 |
| 2010 | 2 | 6 | 8 |
| 2011 | 1 | 6 | 7 |
| 2012 | 1 | 7 | 8 |
| 2013 | 1 | 4 | 5 |
| 2014 | 2 | 7 | 9 |
| 2015 | 2 | 5 | 7 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 6 | 7 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 3 | 4 |
| 2020 | 3 | 4 | 7 |
| 2021 | 1 | 1 | 2 |
| 2022 | 4 | 1 | 5 |
| 2023 | 4 | 1 | 5 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
-
Providers'?use of pharmacogenetic testing to inform opioid prescribing among veterans. Pharmacogenomics. 2024; 25(12-13):495-501.
-
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3478-3490.
-
Pharmacogenomic insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6 copy number variation, and phenoconversion in 15,000 patients. Mol Psychiatry. 2024 Nov; 29(11):3495-3502.
-
Empowering personalized pharmacogenomics with generative AI solutions. J Am Med Inform Assoc. 2024 May 20; 31(6):1356-1366.
-
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681.
-
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2024 03; 115(3):576-594.
-
Should secondary pharmacogenomic variants be actively screened and reported when diagnostic genome-wide sequencing is performed in a child? Genet Med. 2024 02; 26(2):101033.
-
A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na?ve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr; 49(5):893-902.
-
Child and adolescent psychiatrists' use, attitudes, and understanding of genetic testing and pharmacogenetics in clinical practice. Psychiatry Res. 2023 07; 325:115246.